Sector Challenges Medical Law
- MADRID (May 1, 2025) — Spain's innovative pharmaceutical industry is expressing reservations about the draft Law of Medicines and Health Products, emphasizing the need for a stable regulatory...
- While engaging with the Ministry of Health to capitalize on what it sees as a pivotal opportunity to modernize the nation's healthcare system for the next two decades,...
- A primary objection revolves around the proposed pricing system for off-patent medications.
Spain’s Pharmaceutical industry Voices Concerns Over Proposed Drug Law
Table of Contents
- Spain’s Pharmaceutical industry Voices Concerns Over Proposed Drug Law
- Industry Seeks Collaborative Transformation
- Pricing System Under Scrutiny
- Call for Timely Access to Innovative Medicines
- Generics Sector Seeks Dynamic Pricing Model
- Generics Industry Defends Pricing Amidst Rising Costs
- Strategic Autonomy in Manufacturing
- Long-Term Vision for Healthcare Investment
- Economic Impact Concerns
- Investment in Innovation and Production
- Tariff threat looms
- Spain’s Pharmaceutical Industry: Key Concerns Over Proposed Drug law – A Q&A
MADRID (May 1, 2025) — Spain’s innovative pharmaceutical industry is expressing reservations about the draft Law of Medicines and Health Products, emphasizing the need for a stable regulatory environment to foster investment and development. farmaindustria, the leading industry association, articulated these concerns as the period for submitting allegations draws to a close.
Industry Seeks Collaborative Transformation
While engaging with the Ministry of Health to capitalize on what it sees as a pivotal opportunity to modernize the nation’s healthcare system for the next two decades, Farmaindustria has identified key areas of contention. Fina Lladós, president of Farmaindustria, stated the industry’s desire to “transform our health and prepare it for the next 20 years” through constructive dialog.
Pricing System Under Scrutiny
A primary objection revolves around the proposed pricing system for off-patent medications. The industry is united in its opposition to the measure, which would implement biannual price reductions through a blind bidding process. Critics argue this approach could exacerbate supply chain vulnerabilities, harm the industrial base, and negatively impact both patients and prescribers.
Call for Timely Access to Innovative Medicines
Farmaindustria is advocating for reforms to the financing and pricing model to ensure patients gain access to new drugs within 180 days, aligning with clarity directives. Furthermore, they are pushing for an expedited 90-day approval process for funding medicines targeting rare, serious, or debilitating conditions where alternative treatments are lacking.
Generics Sector Seeks Dynamic Pricing Model
Despite a unified public stance, Ángel Luis Rodríguez de la Cuerda, the outgoing general secretary of the Association of GENERIC MEDICINES (AESEG), noted ongoing dialogue with authorities. AESEG is proposing a dynamic pricing model,linked to sales volume,as an alternative to the “blind price system” outlined in Article 116 of the proposed law. This article has drawn criticism from across the pharmaceutical sector, including manufacturers, distributors, and pharmacies.
Generics Industry Defends Pricing Amidst Rising Costs
In response to claims from the Health Ministry regarding the comparatively high cost of generic drugs in Spain relative to countries like Denmark and Sweden, AESEG emphasizes that half of all generics sold in Spain are priced below 1.60 euros at the laboratory sale price. The association also points to increased costs stemming from the war in Ukraine, the energy crisis, and evolving European wastewater regulations.
Strategic Autonomy in Manufacturing
AESEG argues against comparisons with nations lacking domestic manufacturing infrastructure and reliant on laboratories in India and China, especially given Europe’s strategic objective of achieving greater autonomy in pharmaceutical production.
Long-Term Vision for Healthcare Investment
During a New Economy Forum event,Lladós underscored the significance of the new law,intended to replace legislation dating back to 1996 and amended in 2006. She emphasized the transformative potential of data science and artificial intelligence in drug research, stating, “Health, health care, medicines have changed a lot sence then, and for good, but above all, it will change much more in the coming years.”
Economic Impact Concerns
While aligned on overarching goals, Farmaindustria contends that the current draft law is not conducive to the industry, patients, or healthcare professionals. Lladós characterized the draft as having a short-term economic focus, primarily aimed at reducing public spending.She advocated for viewing medication and healthcare as a valuable economic and social investment for Spain, generating significant medium- and long-term benefits across health, social, and economic spheres.
According to the preliminary draft’s economic impact assessment, the proposed regulations could result in an economic setback of nearly 1 billion euros for the pharmaceutical sector.
Investment in Innovation and Production
Farmaindustria is urging increased investment in healthcare, a commitment to biopharmaceutical innovation and new technologies, and the promotion of medicine production within Europe and Spain. The aim is to ensure timely access to innovative treatments for Spanish society.
A report by Financial Analysts indicates that the public sector’s nearly 22 billion euro investment in medicines in 2022 yielded savings of 14.2 billion euros in other budgetary areas. The pharmaceutical industry’s multiplier effect also generates over 27 billion euros in added value, according to Farmaindustria.
Tariff threat looms
Lladós also addressed the potential consequences of the united States imposing 25% tariffs on European pharmaceutical products. Such a measure could increase production costs in Europe by 30 billion euros and jeopardize 85% of long-term asset investments and 50% of research and development investments in europe. “In total, it would put more than 100,000 million euros of investment at risk in the 2025-2029 period,” she warned.
Spain’s Pharmaceutical Industry: Key Concerns Over Proposed Drug law – A Q&A
The primary concern revolves around the proposed pricing system for off-patent medications and its potential impact on the pharmaceutical industry, investment, and, ultimately, patient access to medicines. Farmaindustria, the leading industry association, is notably vocal in its reservations. They highlight the need for a stable regulatory surroundings to foster investment and growth in Spain’s sector.
The industry objects to the implementation of biannual price reductions through a “blind bidding” process. Critics, including Farmaindustria, argue that this approach could create notable challenges. They believe it may exacerbate supply chain vulnerabilities, damage the industrial base within spain’s borders, and ultimately negatively affect both patients and healthcare prescribers.
Besides the pricing system, Farmaindustria is also advocating for reforms in the financing and pricing model more broadly, aiming to ensure patients receive access to new drugs within 180 days, in alignment with clarity directives. They’re further pushing for a faster approval process of just 90-days for funding medicines targeted towards rare, serious, or debilitating conditions where effective option treatments are scarce or nonexistent.
While united to some degree, the association of GENERIC MEDICINES (AESEG) is voicing its own perspective. They’re proposing a dynamic pricing model tied to sales volume as an alternative to the “blind price system” outlined in Article 116 of the proposed law that is generating friction. This article has drawn criticism from various facets of the pharmaceutical space,including manufacturers,distributors,and even pharmacies.
AESEG emphasizes that half of all generics sold in Spain are priced below €1.60 at the laboratory sale price. The association also attributes increased costs to the effects of the war in Ukraine, the ongoing energy crisis, and evolving European wastewater regulations that affect manufacturers. They suggest that comparisons with nations without a domestic manufacturing infrastructure are not appropriate, especially given Europe’s desire for greater autonomy in pharmaceutical production.
The industry association is urging increased investment in healthcare, a strong commitment to biopharmaceutical innovation, and the promotion of domestic medicine production within Europe, especially Spain. This is considered essential for ensuring patients’ timely access to innovative medicines. They highlight the transformative potential of technologies such as data science and artificial intelligence in drug research and development..
According to preliminary economic impact assessments, the proposed regulations could lead to an economic downturn of nearly 1 billion euros for the pharmaceutical sector. Farmaindustria’s perspective is that medicine and healthcare represent valuable long-term economic and social investments for Spain.in contrast to a focus on spending cuts, the industry recommends considering broader benefits when assessing fiscal policy.
farmaindustria highlights that a public sector investment of nearly 22 billion euros in medicines in 2022 yielded savings of 14.2 billion euros in other budgetary areas, according to Financial Analysts reports. Moreover, the pharmaceutical industry’s multiplier effect and overall contribution generate over 27 billion euros in added value.
The imposition of 25% tariffs by the United States on European pharmaceutical products could have severe consequences and is a significant concern. This could increase production costs in Europe by 30 billion euros and possibly jeopardize 85% of long-term asset investments.Further it could also threaten 50% of research and development investments in Europe overall. A full impact would potentially put over 100,000 million euros in investment at risk between 2025 and 2029,as noted by fina Lladós.
Key Takeaways
| Issue | Industry Concerns |
|---|---|
| Pricing System for Off-Patent Drugs | “Blind bidding” could harm supply chains, industrial base, patients, and prescribers. |
| Access to Innovative Medicines | Need for faster approval processes and access times. |
| Investment | Emphasis on fostering a favorable regulatory environment to attract and retain investment. |
| Economic Impact | Potential for economic setback; industry highlights its contribution through savings and added value. |
| US Tariffs | Significant risks to investment and production due to potential US tariffs. |
Disclaimer: This article is based on the provided text and aims to provide an overview of the situation. It is indeed not intended to be financial or legal advice.